Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Choline + aspirin is a combination of two agents—choline, an essential nutrient and α7 nicotinic receptor agonist, and aspirin (acetylsalicylic acid), a non-steroidal anti-inflammatory drug (NSAID). This combination has been studied for its synergistic analgesic effects in inflammatory pain models. Choline itself exhibits antinociceptive properties via activation of α7 nicotinic receptors, muscarinic receptors, and opioid receptors. When coadministered with aspirin, the combination demonstrates enhanced potency and duration of analgesia compared to either agent alone. The mechanism involves both central and peripheral pathways for pain modulation. While not currently marketed as a fixed-dose pharmaceutical product, this combination is under investigation as a potential safe analgesic regimen for inflammatory pain[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on choline + aspirin.